ADC - New Bull's Eye to Treat Lymphoma
According to a new research report by RNCOS entitled, "Global Antibody Drug Conjugate Market Outlook 2018", around 40% of ADCs under development has been aiming to treat lymphomas. Lymphomas are tumors belonging to the lymphocytes such as B and T cell lymphocytes. There are two main types: Hodgkin Lymphoma and Non Hodgkin Lymphoma, Non Hodgkin Lymphoma makes up about 90% of cases.
View full press release